zinc finger protein 461Genealiases: GIOT-1 · GIOT1 · HZF28
Q-omics provides the consensus-scored ZNF461 profile across patient tissues and cancer cell-line models. ZNF461 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in LGG. Among the 18 cancer types available for tumor–normal comparison, ZNF461 is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, ZNF461 RNA expression shows 20,946 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight LGG, THCA, and THYM as cancer lineages where ZNF461 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF461 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF461 survival associations across molecular data types. ZNF461 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF461 RNA expression–survival associations across cancer types. High ZNF461 expression shows unfavorable associations in LGG, READ and ACC, but favorable associations in KIRC, UCS and BRCA. The LGG Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LGG as the clearest survival context for ZNF461 RNA expression.
This table summarizes ZNF461 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF461. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF461 shows lower tumor expression in THCA, KICH and UCEC and higher tumor expression in LIHC, BRCA and CHOL. The THCA box plot shows higher ZNF461 RNA expression in normal versus tumor tissue (log2 FC = −0.686, t-test p < 0.001).
This table shows molecular features associated with ZNF461 in patient tissues and cancer cell lines. In patient samples, ZNF461 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF461 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LUNG_SCLC.
